



ALK  
Investor Relations Department  
BÅ,ge Alle 6-8  
Horsholm DK-2970  
Denmark

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### OMX: ALKB

Last Trade:	1018.00
Trade Time:	4:59 PM ET May 25, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	646.00 - 1081.00
Volume	N/A

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

## Company releases [\[ View all \]](#)

*May 27, 2018*  
[Allergy experts: "Clinical effect of ALK's tree SLIT-tablet among the most significant ever seen in allergy immunotherapy trials"](#)

*May 4, 2018*  
[Three-month interim report \(Q1\) 2018](#)

*May 1, 2018*  
[Release date of three-month interim report \(Q1\) 2018 and audio cast](#)

*Apr 17, 2018*  
[ALK's partner for Japan, Torii, secures pricing for new Japanese cedar SLIT-tablet](#)

*Apr 11, 2018*  
[ALK announces allergy diagnostic partnership with Rellergen in China](#)

## Upcoming Events [\[ View all \]](#)

*Aug 15, 2018*  
[Six-month interim report \(Q2\) 2018](#)

*Nov 9, 2018*  
[Nine-month interim report \(Q3\) 2018](#)